EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prognostic Markers in Meningioma: Effectiveness of FISH‐Assessed CDKN2A/B Homozygous Deletion and Limits of Surrogate p16/MTAP Immunohistochemistry in Predicting Disease‐Specific Survival

Alessia Andrea Ricci iD, Filippo Nozzoli iD, Alessandro Biale, Cristian Tampieri, Ludovica Verdun di Cantogno, Diego Garbossa, Mario Levis, Roberta Rudà iD, Camilla Bonaudo iD, Alessandro Della Puppa, Lorenzo Livi, Isacco Desideri iD und 2 weitere

Neuropathology and Applied Neurobiology · 2026

DOI: 10.1111/nan.70101 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuropathology and Applied Neurobiology, 2026. Verfasst von Alessia Andrea Ricci und 13 weiteren Autor:innen. Beteiligte Einrichtung: Pathology Unit, Department of Medical Sciences, University of Turin, Turin, Italy. Hauptthemen laut MEDLINE: Cyclin-Dependent Kinase Inhibitor p16, Meningioma, Meningeal Neoplasms, Cyclin-Dependent Kinase Inhibitor p15. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fondazione Ricerca Molinette ETS, Rete Oncologica Piemonte e Valle d'Aosta, Fondazione CRT.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Homozygous deletion (HD) of CDKN2A/B represents an adverse prognostic biomarker in meningiomas and a diagnostic criterion for CNS WHO grade 3 assignment. However, fluorescence in situ hybridisation (FISH) thresholds and the role of immunohistochemistry (IHC) surrogates remain uncertain. This study evaluated multiple CDKN2A/B FISH cutoffs and assessed the diagnostic and prognostic performance of MTAP and p16 IHC. Methods and Results Ninety‐two meningiomas (CNS WHO grades 1–3) were analysed by FISH evaluating ≥ 10%, ≥ 20% and ≥ 30% CDKN2A/B HD thresholds. CDKN2A/B HD was identified in 18.5%, 6.5% and 4.3% of cases using the respective cutoffs and was significantly associated with shorter disease‐specific survival across all thresholds (HD ≥ 10% p = 0.001 ; HD ≥ 20% p = 0.0001; HD ≥ 30% p = 0.043). Patients with HD ≥ 20% and ≥ 30% experienced universal disease‐specific mortality within a median survival time of approximately 2 years. MTAP and p16 IHC were performed in matched areas. MTAP IHC showed high specificity (90%–92%) but limited sensitivity (30%–50%), while p16 IHC displayed variable sensitivity (41%–75%) and lower specificity (63%). Combined MTAP/p16 negativity improved sensitivity (up to 100%) but reduced specificity (57%). Neither MTAP nor p16 loss correlated significantly with survival. Spatially heterogeneous IHC patterns corresponded to regional variability in CDKN2A/B deletion by FISH.

Conclusions

CDKN2A/B HD detected by FISH, particularly using thresholds equal or greater than 20%, is strongly associated with poor outcome in meningiomas. MTAP and p16 IHC, alone or combined, lack sufficient accuracy as independent surrogates but may guide tissue selection for molecular testing in heterogeneous tumours.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cyclin-Dependent Kinase Inhibitor p16MeningiomaMeningeal NeoplasmsCyclin-Dependent Kinase Inhibitor p15Biomarkers, TumorHumansFemaleMalePrognosisIn Situ Hybridization, FluorescenceImmunohistochemistryMiddle AgedAgedAdultPurine-Nucleoside PhosphorylaseGene DeletionAged, 80 and over

Stichwörter der Autor:innen

CDKN2A/B deletionMTAPfluorescence in situ hybridisationimmunohistochemistrymeningiomamolecular pathologyp16prognosis

Substanzen

Cyclin-Dependent Kinase Inhibitor p16Cyclin-Dependent Kinase Inhibitor p15Biomarkers, Tumor5'-methylthioadenosine phosphorylasePurine-Nucleoside PhosphorylaseCDKN2B protein, humanCDKN2A protein, human

Autor:innen und Institutionen

  • Pathology Unit, Department of Medical Sciences, University of Turin, Turin, Italy.
  • Histopathology and Molecular Diagnostics, Careggi University Hospital, Florence, Italy.
  • Pathology Unit, Department of Laboratory Medicine, "Città della Salute e della Scienza" University Hospital, Turin, Italy.
  • Department of Neuroscience "Rita Levi Montalcini", University of Turin, Turin, Italy.
  • Neurosurgery Unit, "Città della Salute e della Scienza" University Hospital, University of Turin, Turin, Italy.
  • Department of Oncology, University of Turin, Turin, Italy.

ORCID-Profile: Alessia Andrea Ricci, Filippo Nozzoli, Roberta Rudà, Camilla Bonaudo, Isacco Desideri, Paola Cassoni, Luca Bertero

Förderung

  • Fondazione Ricerca Molinette ETS
  • Rete Oncologica Piemonte e Valle d'Aosta
  • Fondazione CRT

Zitieren

APA

Ricci, A. A., Nozzoli, F., Biale, A., Tampieri, C., Verdun di Cantogno, L., Garbossa, D., Levis, M., Rudà, R., Bonaudo, C., Della Puppa, A., Livi, L., Desideri, I., Cassoni, P., & Bertero, L. (2026). Prognostic Markers in Meningioma: Effectiveness of FISH‐Assessed CDKN2A/B Homozygous Deletion and Limits of Surrogate p16/MTAP Immunohistochemistry in Predicting Disease‐Specific Survival. Neuropathology and Applied Neurobiology. https://doi.org/10.1111/nan.70101

Vancouver

Ricci AA, Nozzoli F, Biale A, Tampieri C, Verdun di Cantogno L, Garbossa D, et al. Prognostic Markers in Meningioma: Effectiveness of FISH‐Assessed CDKN2A/B Homozygous Deletion and Limits of Surrogate p16/MTAP Immunohistochemistry in Predicting Disease‐Specific Survival. Neuropathology and Applied Neurobiology. 2026. doi:10.1111/nan.70101

BibTeX
@article{Ricci2026,
  author = {Ricci, Alessia Andrea and Nozzoli, Filippo and Biale, Alessandro and Tampieri, Cristian and Verdun di Cantogno, Ludovica and Garbossa, Diego and Levis, Mario and Rudà, Roberta and Bonaudo, Camilla and Della Puppa, Alessandro and Livi, Lorenzo and Desideri, Isacco and Cassoni, Paola and Bertero, Luca},
  title = {Prognostic Markers in Meningioma: Effectiveness of FISH‐Assessed CDKN2A/B Homozygous Deletion and Limits of Surrogate p16/MTAP Immunohistochemistry in Predicting Disease‐Specific Survival},
  journal = {Neuropathology and Applied Neurobiology},
  year = {2026},
  doi = {10.1111/nan.70101}
}
Kostenlos starten →